Dr Bijal Shah speaks to ecancer about the phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia.

Initially, he explains the rationale of this study.

Dr Shah then discusses the methodology and key findings of this study.

He mentions that as of 9/2020, 55 of 71 enrolled patients received KTE-X19, with a median follow-up of 16.4 months. Adverse events and ineligibility were the most common reasons enrolled patients did not receive KTE-X19 infusion.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.